|Year : 2019 | Volume
| Issue : 5 | Page : 155-160
Blue-light cystoscopy and narrow-band imaging in bladder cancer management
Zhijiang Zang, Qinghui Wu, Edmund Chiong
Department of Urology, National University Health System, Singapore 119228, Singapore
|Date of Submission||18-Dec-2018|
|Date of Decision||07-Jan-2019|
|Date of Acceptance||10-Apr-2019|
|Date of Web Publication||25-Oct-2019|
Prof. Edmund Chiong
Department of Urology, National University Health System, NUHS Tower Block, Level 8, 1E Kent Ridge Road, Singapore 119228
Source of Support: None, Conflict of Interest: None
Despite the high resolution of modern imaging technology including computed tomography and magnetic resonance imaging, cystoscopy remains the gold standard method for detecting bladder cancer. Cystoscopy is conventionally conducted with white light visualization, and the pitfalls of white light cystoscopy are well-recognized. Novel technologies to enhance visualization of bladder lesion have emerged during the past 20 years. Among them, blue-light cystoscopy (BLC) and narrow-band imaging (NBI) are the most promising and well-studied. Many clinical trials have suggested the benefit of these two technologies. In this review, we aim to summarize the data, evidence, and current role of BLC and NBI in clinical practice.
Keywords: Bladder cancer, blue-light cystoscopy, narrow-band imaging
|How to cite this article:|
Zang Z, Wu Q, Chiong E. Blue-light cystoscopy and narrow-band imaging in bladder cancer management. Formos J Surg 2019;52:155-60
|How to cite this URL:|
Zang Z, Wu Q, Chiong E. Blue-light cystoscopy and narrow-band imaging in bladder cancer management. Formos J Surg [serial online] 2019 [cited 2020 May 31];52:155-60. Available from: http://www.e-fjs.org/text.asp?2019/52/5/155/269924
| Introduction|| |
Bladder cancer is the seventh-most common cancer worldwide in men, affecting more than 800,000 people. Up to 85% of cancer in the bladder is nonmuscle invasive bladder cancer (NMIBC), which is treated with bladder-sparing therapies (e.g., transurethral resection of bladder tumor [TURBT] coupled with immunotherapy or chemotherapy). Despite treatment, bladder cancer still has an extremely high cancer recurrence rate after tumor resection. The recurrence rate is 15%–61% after 1 year and 31%–78% after 5 years. Moreover, up to 17% of the NMIBC will progress to a muscle-invasive tumor after 1 year and 45% after 5 years, respectively. Long-term surveillance is mandatory after bladder-retaining therapies in bladder cancer.
The high recurrence rate of bladder cancer has been linked to overlooked tumors and inadequately resected tumors. White light cystoscopy (WLC), the current mainstay method, is known to miss occult bladder lesions such as small multifocal tumors and carcinoma in situ (CIS)., Better visualization of bladder tumors has been achieved using novel optical technologies. Among them, blue-light cystoscopy (BLC) and narrow-band imaging (NBI) are the most well-studied. Both of the technologies have been approved by the Food and Drug Administration (FDA) for their applications in NMIBC diagnosis and treatment.
| Mechanism|| |
BLC is also known as fluorescence cystoscopy or photodynamic diagnosis (PDD) of bladder tumor. It involves detection of bladder lesions using fluorescence. To generate fluorescence, photosensitizers such as hypericin and hematoporphyrin derivatives such as 5-aminolevulinic acid and hexaminolevulinate (HAL) hydrochloride are introduced into the bladder. BLC first emerged in 1996. In 2010, the FDA approved HAL as the only photosensitizer for bladder cancer detection. Intravesical incubation of HAL induces significant intracellular levels of protoporphyrin IX (PpIX) and other photoactive porphyrins (PAPs), which act as photosensitizers. PpIX and PAPs are preferentially accumulated in neoplastic or highly-proliferative cells due to the altered enzyme activities within these cells. This leads to the bright-red fluorescence of neoplastic tissues at wavelengths between 360 and 450 nm while the normal surrounding tissues display dark blue.
In contrast, NBI is an optical image enhancement technology that does not depend on any biochemical synthesis. It involves two specific wavelengths of light (415 nm and 540 nm) which are strongly absorbed by hemoglobin. The 415 nm light mainly penetrates superficial layers of the bladder mucosa. It is absorbed by superficial blood vessels and appears brownish. The 540 nm light can reach a deeper layer of the bladder mucosa. It is absorbed by deeper blood vessels and gives off a cyan coloring. Compared to white light, NBI allows for the better detection of highly-vascularized abnormal tissues. This makes it a useful tool in detecting bladder tumors during cystoscopy. In 2014, FDA approved the application of NBI in bladder cancer management.
| Impact on Tumor Detection|| |
BLC and NBI are significant technical advances in the field of bladder cancer management during the past two decades. Both offer several advantages over conventional WLC. First, BLC and NBI improve the detection rate of bladder tumors.,, The better sensitivities are more pronounced in CIS and small lesions. On an average, BLC with HAL detected 14.7% more Ta and 40.8% more CIS lesions compared to WLC, based on a meta-analysis of six studies comprising 1345 patients. About 24.9% of patients with at least one additional Ta/T1 tumor were seen with BLC.
Similarly, NBI has also superior sensitivity over WLC at per-patient (95.8% vs. 81.6%) and per-lesion levels (94.8% vs. 72.4%) in detecting NMIBC. NBI cystoscopy allows detection of 9.9% more bladder cancer patients or 18.6% more bladder tumors that would otherwise be missed by WLC. When comparing the performance of BLC and NBI directly, both technologies had similar superior sensitivity in detecting bladder CIS and dysplasia compared to WLC (NBI: 95.7%, PDD: 95.7% vs. WLC: 65.2%, P < 0.05).
| Impact on Tumor Recurrence Rate|| |
More importantly, BLC- and NBI-assisted TURBT reduce the recurrence rate of bladder cancer after resection.,, This is likely due to improved visualization of tumor margins as well as occult lesions during TURBT. Most of the randomized controlled clinical trials using BLC-assisted TURBT with HAL support this conclusion.,,,,, BLC-assisted TURBT with HAL had a lower 12 months cancer recurrence rate (34.5%) compared to that of WLC-assisted TURBT (45.4%) overall (P = 0.006). This difference is significant regardless of risk group (high vs. low risk) and clinical stage (Ta vs. T1 vs. CIS group). Long-term follow-up (median follow-up time 36.6 months) of BLC-assisted TURBT with HAL confirmed that it reduced recurrence risk (39% vs. 53.3%, P = 0.02) compared to WLC. It is worthy to note that a single shot of early postoperative intravesical mitomycin C was given to all patients in this trial, demonstrating that the benefit of BLC-assisted TURBT on reducing the cancer recurrence was not diminished by early postoperative single-shot mitomycin C.,
Naselli et al. reported that NBI-assisted TURBT reduced the recurrence risk of NMIBC by at least 10% at 1 year. A study by Naito et al. found a better 12-months (5.6% vs. 27.3%, P = 0.02) recurrence rate of NBI-assisted TURBT versus WLC-assisted TURBT in low-risk bladder cancer patients but not in intermediate- or high-risk group. However, the use of adjuvant intravesical instillation therapy was not documented in this trial. The authors hypothesized that the recurrence in intermediate- or high-risk patients may be caused not only by the overlooked small tumors but also by regrowth of high-grade tumor cells disseminated during TURBT. A recent meta-analysis comprising six trials confirmed that NBI-TURBT reduces the 3 months, 1 year, and 2 years cancer recurrence risk when compared to WLC-TUR (P< 0.01 for all).
| Impact on Tumor Progression and Survival|| |
Even though BLC and NBI-assisted TURBT reduces the recurrence rate of bladder cancer, the two technologies do not appear to decrease the rate of disease progression into muscle-invasive bladder cancer significantly., Furthermore, most of the evidence suggests that BLC or NBI-assisted TURBT do not improve cancer-specific mortality or overall mortality;, although there are conflicting reports.
| Impact on Patients With Positive Urine Cytology but Negative White Light Cystoscopy|| |
BLC and NBI are particularly valuable in evaluating patients with positive urine cytology but negative WLC, which is a clinical challenge that conventionally requires more aggressive approaches such as bilateral ureteroscopy, urine sampling, and random prostate and bladder biopsies under general anesthesia. Using BLC, Karl et al. were able to pinpoint the precise lesion locations in 63 of 77 (83%) patients with positive urine cytology but negative WLC. The identified lesions included 18 moderate dysplasia, 27 carcinomas in situ (CIS), and 18 pTa-1/G1-3 tumors. Continuous surveillance (median 8.5 months) of the 14 remaining patients who had positive urine cytology and first negative BLC identified another eight patients with neoplastic disease. Zhu et al. conducted NBI and biopsy for 12 patients with positive or suspicious urine cytology but negative WLC. NMIBC was diagnosed in 5 of 12 (42%) patients on the first NBI. One patient had CIS on the repeated NBI 3 months later.
| Limitations and Concerns|| |
Neither BLC-assisted nor NBI-assisted visualization is cancer-specific. Thus, the main concern of the two technologies is false positivity of tumor detection, which leads to unnecessary biopsy and resection. In Kausch's meta-analysis, all six studies using BLC with HAL had higher false-positive detection rates on lesion basis, ranging from 11% to 39% versus 9% to 31% in the WLC groups. Nevertheless, other investigators found that the false positivity of BLC is not statistically different from WLC., In addition, Xiong et al. found that the specificity of NBI is significantly lower when compared to WLC (73.6% vs. 79.2% at the per-patient level and 65.6% vs. 79.1% at the per-lesion level).
The false positivity of BLC and NBI could be contributed by both lesion factor and operator factor. The inflammatory changes of the bladder mucosa may mimic malignant/premalignant alterations under BLC and NBI., Individual surgeon variability on lesion visualization and assessment can also be a problem. Palou et al. described wide variability on the false-positive rate (6.1%–39.3%) in BLC with HAL involving eight Spanish medical centers. In a NBI study, individual surgeon variability of diagnosis specificities was noted from three expert urologists (79%, 58%, and 79%) and one trainee urologist (67%), although no significant difference was found overall. To control false positivity, both techniques are contraindicated in patients with active gross hematuria, intravesical Bacillus Calmette-Guerin or chemotherapy or TURBT within 90 days. About 10–30 training procedures are recommended to achieve good agreement between surgeons.,
In addition, BLC and NBI were performed after WLC in the vast majority of the studies, raising the concerns that the better sensitivity of bladder cancer detection of BLC and NBI might arise from “2nd look” cystoscopy. Shen et al. compared the results from NBI followed by WLC verses WLC followed by NBI. They concluded that the “second look” did not compromise the superiority of NBI over WLC.
Both technologies require investments in hardware. BLC requires the extra cost of HAL after equipment setup. Concerns have been raised regarding the cost-effectiveness of the two technologies, given that bladder cancer is the most expensive human malignancy to treat. Studies suggest the overall cost of bladder cancer management can be reduced by the lower recurrence rate of BLC-assisted TURBT. Similarly, the reduced cancer recurrence rate of NBI-assisted TURBT may justify the investment of NBI hardware, although no cost-effectiveness study of NBI has been published yet.
| Adverse Effects|| |
Small risks (<2%–3%) of bladder spasm, dysuria, hematuria, bladder pain, and headache have been linked to BLC with HAL, yet none of the above has been classified as probably or definitely related to HAL. While no serious adverse events (AEs) were directly related to HAL, the potential risk of anaphylactoid AE after repeated administration of HAL has been a concern traditionally. Thus, the FDA has only approved HAL for single use in the USA. However, recent studies have suggested the excellent safety profile of HAL even after repeated administration.,
| Guidelines and Recommendations|| |
In view of the compelling evidence, clinical guidelines of NMIBC of all major urology associations recommend incorporating BLC and NBI technology into clinical practice [Table 1].,,, Overall, the level of evidence of BLC is stronger than NBI, likely reflecting the fact that NBI is a more recent technology and fewer trials have been done. Nevertheless, NBI is a promising alternative of BLC in view of its efficiency, simplicity, and other characteristics [Table 2].
|Table 1: Evidence and recommendations on BLC and NBI in the latest guidelines of NMIBC of AUA, SUO, EAU, NCCN and NICE|
Click here to view
|Table 2: Comparison of characteristics of narrow-band imaging and blue-light cystoscopy technology|
Click here to view
| Conclusion|| |
Both BLC and NBI enhance the visualization of bladder CIS, small lesions as well as tumor margins during TURBT, and reduce short-term and long-term cancer recurrence rate. The two enhanced cystoscopy modalities are valuable additions to WLC considering that bladder cancer remains as one of the most frequently recurrent human cancer types after tumor resection currently. To control false positivity, doctors should acquire adequate training and adhere to contraindications. More works are needed to further define the impact of BLC and NBI on progression-free survival in bladder cancer management.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al.
Epidemiology of urinary bladder cancer: From tumor development to patient's death. World J Urol 2007;25:285-95.
Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al.
Areview of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. J Urol 2011;186:2158-67.
Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem el-HI, Nabeeh A, Ghoneim MA. Superficial bladder tumours: Analysis of prognostic factors and construction of a predictive index. BJU Int 2003;92:393-9.
Herr HW. Intravesical BCG: Current results, natural history and implications for urothelial cancer prevention. J Cell Biochem Suppl 1992;16I: 112-9.
Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-8.
Kriegmair M, Baumgartner R, Knüchel R, Stepp H, Hofstädter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-9.
Altobelli E, Zlatev DV, Liao JC. Role of narrow band imaging in management of urothelial carcinoma. Curr Urol Rep 2015;16:58.
Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, et al.
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: A critical review of the current literature. Eur Urol 2013;64:624-38.
Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, et al.
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846-54.
Xiong Y, Li J, Ma S, Ge J, Zhou L, Li D, et al.
Ameta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One 2017;12:e0170819.
Drejer D, Béji S, Oezeke R, Nielsen AM, Høyer S, Bjerklund Johansen TE, et al.
Comparison of white light, photodynamic diagnosis, and narrow-band imaging in detection of carcinoma in situ
or flat dysplasia at transurethral resection of the bladder: The daBlaCa-8 study. Urology 2017;102:138-42.
Kang W, Cui Z, Chen Q, Zhang D, Zhang H, Jin X. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis. Oncotarget 2017;8:23880-90.
Lee JY, Cho KS, Kang DH, Jung HD, Kwon JK, Oh CK, et al.
Anetwork meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs. hexylaminolevulinate fluorescence vs. narrow band imaging. BMC Cancer 2015;15:566.
Gallagher KM, Gray K, Anderson CH, Lee H, Stewart S, Donat R, et al.
'Real-life experience': Recurrence rate at 3 years with hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study. World J Urol 2017;35:1871-7.
Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al.
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907-13.
Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al.
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58-62.
Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in ta/T1 patients: A randomized two-centre study. BJU Int 2011;108:E297-303.
Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: Does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 2012;109:549-56.
O'Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs. conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 2013;112:1096-104.
Pietzak EJ. The impact of blue light cystoscopy on the diagnosis and treatment of bladder cancer. Curr Urol Rep 2017;18:39.
Naselli A, Introini C, Timossi L, Spina B, Fontana V, Pezzi R, et al.
Arandomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol 2012;61:908-13.
Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, et al.
The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: Trial protocol and 1-year results. Eur Urol 2016;70:506-15.
Yuan H, Qiu J, Liu L, Zheng S, Yang L, Liu Z, et al.
Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: A meta-analysis of randomized controlled trials. PLoS One 2013;8:e74142.
May M, Fritsche HM, Vetterlein MW, Bastian PJ, Gierth M, Nuhn P, et al.
Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: Results from PROMETRICS 2011. World J Urol 2017;35:245-50.
Shen P, Yang J, Wei W, Li Y, Li D, Zeng H, et al.
Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: A systematic review and meta-analysis. BJU Int 2012;110:E209-15.
Gakis G, Ngamsri T, Rausch S, Mischinger J, Todenhöfer T, Schwentner C, et al.
Fluorescence-guided bladder tumour resection: Impact on survival after radical cystectomy. World J Urol 2015;33:1429-37.
Karl A, Tritschler S, Stanislaus P, Gratzke C, Tilki D, Strittmatter F, et al.
Positive urine cytology but negative white-light cystoscopy: An indication for fluorescence cystoscopy? BJU Int 2009;103:484-7.
Zhu YP, Shen YJ, Ye DW, Wang CF, Yao XD, Zhang SL, et al.
Narrow-band imaging flexible cystoscopy in the detection of clinically unconfirmed positive urine cytology. Urol Int 2012;88:84-7.
Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al.
Photodynamic diagnosis in non-muscle-invasive bladder cancer: A systematic review and cumulative analysis of prospective studies. Eur Urol 2010;57:595-606.
Lapini A, Minervini A, Masala A, Schips L, Pycha A, Cindolo L, et al.
Acomparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: Results of the heRo observational study. Surg Endosc 2012;26:3634-41.
Draga RO, Bosch JL, Grimbergen MC. Noninvasive transitional cell carcinoma is associated with a high occurrence of false positives in photodynamic diagnosis. Eur Urol 2009;56:1095-6.
Song PH, Cho S, Ko YH. Decision based on narrow band imaging cystoscopy without a referential normal standard rather increases unnecessary biopsy in detection of recurrent bladder urothelial carcinoma early after intravesical instillation. Cancer Res Treat 2016;48:273-80.
Palou J, Hernández C, Solsona E, Abascal R, Burgués JP, Rioja C, et al.
Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: A Spanish multicentre observational study. BJU Int 2015;116:37-43.
Herr H, Donat M, Dalbagni G, Taylor J. Narrow-band imaging cystoscopy to evaluate bladder tumours – individual surgeon variability. BJU Int 2010;106:53-5.
Gravas S, Efstathiou K, Zachos I, Melekos MD, Tzortzis V. Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride? Can J Urol 2012;19:6269-73.
Shen YJ, Zhu YP, Ye DW, Yao XD, Zhang SL, Dai B, et al.
Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: A “second look” matters? Int Urol Nephrol 2012;44:451-7.
Hedelin H, Holmäng S, Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 2002;36:344-7.
Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al.
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: Evidence review and updated expert recommendations. Eur Urol 2014;66:863-71.
Witjes JA, Gomella LG, Stenzl A, Chang SS, Zaak D, Grossman HB. Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. Urology 2014;84:122-6.
Lane GI, Downs TM, Soubra A, Rao A, Hemsley L, Laylan C, et al.
Tolerability of repeat use of blue light cystoscopy with hexaminolevulinate for patients with urothelial cell carcinoma. J Urol 2017;197:596-601.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al.
Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016;196:1021-9.
[Table 1], [Table 2]